Sinopharm Capital and the WuXi AppTec-backed 6 Dimensions Capital are among the investors in the inflammatory and autoimmune disease drug developer.

Kira Pharmaceuticals, a US-based biotechnology developer focused on immune-mediated diseases, emerged from stealth yesterday with a total of $46m from investors including Sinopharm Capital, the investment arm of pharmaceutical firm Sinopharm.

The cash also came from 6 Dimensions Capital, an investment firm co-founded by pharmaceutical group WuXi AppTec, as well as venture capital firms Quan Capital and Qiming Venture Partners.

Quan Capital was identified as the lead investor by Kira, and Endpoints News reported the company had secured $18m in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn